Partners in Kalypsys Success
Kalypsys has raised over $150 million from recognized and respected healthcare investors that are committed to our success in delivering next generation medicines. Our investors provide the company with sound financial advice and unique scientific acumen. Our strong cash position provides a solid foundation for our ongoing discovery and development initiatives. Our investors include 5AM Ventures, Aravis Ventures, CMEA Ventures, Innovis Investments, Invemed Associates, KT Venture Group, and Novartis Bio Venture Fund, Sprout Group and Tavistock Life Sciences.
Partnerships that Promote Your Success
Kalypsys’ major partnering interest is in establishing a limited number of R&D alliances in which the parties work collaboratively to advance therapeutic area programs from target screening to clinical candidates and beyond. In addition, Kalypsys is pursuing specific product licensing arrangements.
Please contact Jackie Gulick at jgulick@kalypsys.com with specific inquiries or go just go to Partnering.
